Healthcare :: Innovative pulmonary & PEGylation-based therapeutic product dev. drives business strategy of Nektar
Innovative pulmonary and PEGylation-based therapeutic product development is the focus of two new business units recently created at Nektar Therapeutics (Nasdaq: NKTR), the company announced today.